CoChat
Sign Up
Cited by 39Immunotherapy and Immune ResponsesRNA Interference and Gene DeliveryRNA and protein synthesis mechanisms

Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics

Open access
Kuhn, Andreas N., Diken, Mustafa, Kreiter, Sebastian, Vallazza, Britta, Türeci, Özlem, Sahin, Ugur·2011·RNA Biology
DOI 10.4161/rna.8.1.13767
Open this paper in CoChat — free accountOpen PDF

Abstract

RNAs with optimized properties are increasingly investigated as a tool to deliver the genetic information of complete antigens into professional antigen-presenting dendritic cells for HLA haplotype-independent antigen-specific vaccination against cancer. As the dose of the antigen and duration of its presentation are critical factors for generating strong and sustained antigen-specific immune responses, improvement of the immunobioavailability of RNA-based vaccines has been a recurrent subject of research. Substantial increase of the amount of antigen produced from RNA can be achieved by optimizing RNA stability and translational efficiency. Both features are determined by cis-acting elements in the RNA, namely the 5' cap, the poly(A) tail, and the sequence of the coding and non-coding regions, which interact with corresponding trans-acting factors. This article summarizes recent developments in identifying optimized RNA for expression of foreign proteins in dendritic cells, as well as their implications for immunotherapy based on antigen-encoding RNA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/rna.8.1.13767

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • COVID-19 vaccines required intramuscular administration of mRNA-LNP and expression of the mRNA-encoded antigen in antigen-presenting cells such as dendritic cells to induce a protective immune response.

    “COVID-19 vaccines required intramuscular administration of mRNA-LNP and expression of the mRNA-encoded antigen in antigen-presenting cells such as dendritic cells (DC) to induce a protective immune response.34”

    From Evaluation of synthetic mRNA with selected UTR sequences and alternative poly(A) tail, in vitro and in vivo (2025) · cites this paper as [34]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 93

  1. Jemielity J, Fowler T, Zuberek J, Stepinski J, Lewdorowicz M, Niedzwiecka A, et al. Novel "anti- reverse" cap analogs with superior translational prop- erties. RNA 2003; 9:1108-22.
  2. Mockey M, Goncalves C, Dupuy FP, Lemoine FM, Pichon C, Midoux P. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun 2006; 340:1062-8.
  3. Bontkes HJ, Kramer D, Ruizendaal JJ, Kueter EWM, van Tendeloo VFI, Meijer CJLM, et al. Dendritic cells transfected with interleukin-12 and tumor-asso- ciated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther 2007; 14:366-75.
  4. Kuhn AN, Diken M, Kreiter S, Selmi A, Kowalska J, Jemielity J, et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 2010; 17:961-71.
  5. Hernando JJ, Park TW, Fischer HP, Zivanovic O, Braun M, Polcher M, et al. Vaccination with den- dritic cells transfected with mRNA-encoded folate- receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol 2007; 8:451-4.
  6. Kore AR, Shanmugasundaram M, Charles I, Cheng AM, Barta TJ. Synthesis and application of 2'-fluoro- substituted cap analogs. Bioorg Med Chem Lett 2007; 17:5295-9.
  7. Kore AR, Shanmugasundaram M, Vlassov AV. Synthesis and application of a new 2',3'-isopropyli- dene guanosine substituted cap analog. Bioorg Med Chem Lett 2008; 18:4828-32.
  8. Kore AR, Shanmugasundaram M, Charles I, Vlassov AV, Barta TJ. Locked nucleic acid (LNA)-modified dinucleotide mRNA cap analogue: synthesis, enzy- matic incorporation and utilization. J Am Chem Soc 2009; 131:6364-5.
  9. Grudzien E, Stepinski J, Jankowska-Anyszka M, Stolarski R, Darzynkiewicz E, Rhoads RE. Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency. RNA 2004; 10:1479-87.
  10. Zuberek J, Jemielity J, Niedzwiecka A, Stepinski J, Wyslouch-Cieszynska A, Stolarski R, Darzynkiewicz E. Influence of the length of the phosphate chain in mRNA 5' cap analogues on their interaction with eukaryotic initiation factor 4E. Nucleosides Nucleotides Nucleic Acids 2003; 22:1707-10.
  11. van Dijk E, Cougot N, Meyer S, Babajko S, Wahle E, Seraphin B. Human Dcp2: a catalytically active mRNA decapping enzyme located in specific cyto- plasmic structures. EMBO J 2002; 21:6915-24.
  12. Grudzien-Nogalska E, Jemielity J, Kowalska J, Darzynkiewicz E, Rhoads RE. Phosphorothioate cap analogs stabilize mRNA and increase translational effi- ciency in mammalian cells. RNA 2007; 13:1745-55.
  13. Kowalska J, Lewdorowicz M, Zuberek J, Grudzien- Nogalska E, Bojarska E, Stepinski J, et al. Synthesis and characterization of mRNA cap analogs contain- ing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophos- phatase DcpS. RNA 2008; 14:1119-31.
  14. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811.
  15. Tan X, Wan Y. Enhanced protein expression by inter- nal ribosomal entry site-driven mRNA translation as a novel approach for in vitro loading of dendritic cells with antigens. Hum Immunol 2008; 69:32-40.
  16. Tcherepanova IY, Adams MD, Feng X, Hinohara A, Horvatinovich J, Calderhead D, et al. Ectopic expres- sion of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol Biol 2008; 9:90.
  17. Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, et al. Modification of antigen encoding RNA increases stability, translational efficacy and T-cell stimulatory capacity of dendritic cells. Blood 2006; 108:4009-17.
  18. Princiotta MF, Finzi D, Qian SB, Gibbs J, Schuchmann S, Buttgereit F, et al. Quantitating pro- tein synthesis, degradation and endogenous antigen processing. Immunity 2003; 18:343-54.
  19. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004; 199:251-63.
  20. Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA-and messenger RNA-based anti- cancer vaccination. Immunol Lett 2008; 115:33-42.
  21. Glisovic T, Bachorik JL, Yong J, Dreyfuss G. RNA- binding proteins and post-transcriptional gene regu- lation. FEBS Lett 2008; 582:1977-86.
  22. Wilusz CJ, Wormington M, Peltz SW. The cap-to- tail guide to mRNA turnover. Nat Rev Mol Cell Biol 2001; 2:237-46.
  23. Coller J, Parker R. Eukaryotic mRNA decapping. Annu Rev Biochem 2004; 73:861-90.
  24. Garneau NL, Wilusz J, Wilusz CJ. The highways and byways of mRNA decay. Nat Rev Mol Cell Biol 2007; 8:113-26.
  25. Houseley J, Tollervey D. The many pathways of RNA degradation. Cell 2009; 136:763-76.
  26. Goldstrohm AC, Wickens M. Multifunctional dead- enylase complexes diversify mRNA control. Nat Rev Mol Cell Biol 2008; 9:337-44.
  27. Liu H, Kiledjian M. Decapping the message: a begin- ning or an end. Biochem Soc Trans 2006; 34:35-8.
  28. Hsu CL, Stevens A. Yeast cells lacking 5'→3' exori- bonuclease 1 contain mRNA species that are poly(A) deficient and partially lack the 5' cap structure. Mol Cell Biol 1993; 13:4826-35.
  29. Houseley J, LaCava J, Tollervey D. RNA-quality control by the exosome. Nat Rev Mol Cell Biol 2006; 7:529-39.
  30. Liu H, Rodgers ND, Jiao X, Kiledjian M. The scav- enger mRNA decapping enzyme DcpS is a member of the HIT family of pyrophosphatases. EMBO J 2002; 21:4699-708.
  31. Schwartz DC, Parker R. Mutations in translation ini- tiation factors lead to increased rates of deadenylation and decapping of mRNAs in Saccharomyces cerevisiae. Mol Cell Biol 1999; 19:5247-56.
  32. Beelman CA, Parker R. Differential effects of trans- lational inhibition in cis and in trans on the decay of the unstable yeast MFA2 mRNA. J Biol Chem 1994; 269:9687-92.
  33. Furuichi Y, LaFiandra A, Shatkin AJ. 5'-Terminal structure and mRNA stability. Nature 1977; 266:235-9.
  34. Sonenberg N, Morgan MA, Merrick WC, Shatkin AJ. A polypeptide in eukaryotic initiation factors that crosslinks specifically to the 5'-terminal cap in mRNA. Proc Natl Acad Sci USA 1978; 75:4843-7.
  35. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999; 68:913-63.
  36. Pasquinelli AE, Dahlberg JE, Lund E. Reverse 5' caps in RNAs made in vitro by phage RNA polymerases. RNA 1995; 1:957-67.
  37. Stepinski J, Waddell C, Stolarski R, Darzynkiewicz E, Rhoads RE. Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl(3'- deoxy)GpppG. RNA 2001; 7:1486-95.
  38. Peng ZH, Sharma V, Singleton SF, Gershon PD. Synthesis and application of a chain-terminating dinucleotide mRNA cap analog. Org Lett 2002; 4:161-4. References
  39. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten origical cases. Clin Orthop Relat Res 1893; 262:3-11.
  40. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220:129-50.
  41. Kantoff PW, Higano CS, Shore ND, Berger R, Small EJ, Penson DF, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med 2010; 363:411-22.
  42. Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Rev Vaccines 2009; 8:51-66.
  43. Chen X, Chang CH, Goldenberg DM. Novel strat- egies for improved cancer vaccines. Expert Rev Vaccines 2009; 8:567-76.
  44. Eisenacher K, Steinberg C, Reindl W, Krug A. The role of viral nucleic acid recognition in dendritic cells for innate and adaptive antiviral immunity. Immunobiology 2007; 212:701-14.
  45. Khabar KS. The AU-rich transcriptome: more than interferons and cytokines, and its role in disease. J Interferon Cytokine Res 2005; 25:1-10.
  46. Scholten KB, Kramer D, Kueter EW, Graf M, Schoedl T, Meijer CJ, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 2006; 119:135-45.
  47. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998; 72:1497-503.
  48. Van den Bosch GA, van Gulck E, Ponsaerts P, Nijs G, Lenjou M, Apers L, et al. Simultaneous activation of viral antigen-specific memory CD4 + and CD8 + T-cells using mRNA-electroporated CD40-activated autologous B-cells. J Immunother 2006; 29:512-23.
  49. Van Gulck ER, Ponsaerts P, Heyndrickx L, Vereecken K, Moerman F, de Roo A, et al. Efficient stimulation of HIV-1-specific T cells using dendritic cells elec- troporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 2006; 107:1818-27.
  50. Knights AJ, Nuber N, Thomson CW, de la Rosa O, Jager E, Tiercy JM, et al. Modified tumour antigen- encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother 2009; 58:325-38.
  51. Komar AA. A pause for thought along the co-trans- lational folding pathway. Trends Biochem Sci 2009; 34:16-24.
  52. Kramer G, Boehringer D, Ban N, Bukau B. The ribo- some as a platform for co-translational processing, folding and targeting of newly synthesized proteins. Nat Struct Mol Biol 2009; 16:589-97.
  53. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen- presenting cells in vitro and in vivo. J Exp Med 1996; 184:465-72.
  54. Grunebach F, Muller MR, Nencioni A, Brossart P. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 2003; 10:367-74.
  55. Yewdell JW, Nicchitta CV. The DRiP hypoth- esis decennial: support, controversy, refinement and extension. Trends Immunol 2006; 27:368-73.
  56. Reis e Sousa C. Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol 2004; 16:27-34.
  57. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-31.
  58. Sjöberg EM, Suomalainen M, Garoff H. A signifi- cantly improved Semliki Forest virus expression sys- tem based on translation enhancer segments from the viral capsid gene. Biotechnology 1994; 12:1127-31.
  59. Frolov I, Schlesinger S. Translation of Sindbis virus mRNA: analysis of sequences downstream of the ini- tiating AUG codon that enhance translation. J Virol 1996; 70:1182-90.
  60. Garneau NL, Sokoloski KJ, Opyrchal M, Neff CP, Wilusz CJ, Wilusz J. The 3' untranslated region of sindbis virus represses deadenylation of viral tran- scripts in mosquito and Mammalian cells. J Virol 2008; 82:880-92.
  61. Garfinkel MS, Katze MG. Translational control by influenza virus. Selective and cap-dependent transla- tion of viral mRNAs in infected cells. J Biol Chem 1992; 267:9383-90.
  62. Holden KL, Harris E. Enhancement of dengue virus translation: role of the 3' untranslated region and the terminal 3' stem-loop domain. Virology 2004; 329:119-33.
  63. Chiu WW, Kinney RM, Dreher TW. Control of translation by the 5'-and 3'-terminal regions of the dengue virus genome. J Virol 2005; 79:8303-15.
  64. Bergman N, Moraes KC, Anderson JR, Zaric B, Kambach C, Schneider RJ, et al. Lsm proteins bind and stabilize RNAs containing 5' poly(A) tracts. Nat Struct Mol Biol 2007; 14:824-31.
  65. Sjöberg EM, Garoff H. The translation-enhancing region of the Semliki Forest virus subgenome is only functional in the virus-infected cell. J Gen Virol 1996; 77:1323-7.
  66. Strong TV, Hampton TA, Louro I, Bilbao G, Conry RM, Curiel DT. Incorporation of beta-globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expression. Gene Ther 1997; 4:624-7.
  67. Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, et al. Efficient presenta- tion of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with mes- senger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain pep- tide. Cancer Res 2003; 63:5587-94.
  68. Malone RW, Felgner PL, Verma IM. Cationic lipo- some-mediated RNA transfection. Proc Natl Acad Sci USA 1989; 86:6077-81.
  69. Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000; 164:5508-14.
  70. Ikemura T. Codon usage and tRNA content in uni- cellular and multicellular organisms. Mol Biol Evol 1985; 2:13-34.
  71. Irwin B, Heck JD, Hatfield GW. Codon pair utiliza- tion biases influence translational elongation step times. J Biol Chem 1995; 270:22801-6.
  72. Bossi L, Ruth JR. The influence of codon context on genetic code translation. Nature 1980; 286:123-7.
  73. Gurvich OL, Baranov PV, Zhou J, Hammer AW, Gesteland RF, Atkins JF. Sequences that direct sig- nificant levels of frameshifting are frequent in coding regions of Escherichia coli. EMBO J 2003; 22:5941-50.
  74. Kudla G, Murray AW, Tollervey D, Plotkin JB. Coding-sequence determinants of gene expression in Escherichia coli. Science 2009; 324:255-8.
  75. Michiels A, Tuyaerts S, Bonehill A, Corthals J, Breckpot K, Heirman C, et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 2005; 12:772-82.
  76. Bernstein P, Peltz SW, Ross J. The poly(A)-poly(A)- binding protein complex is a major determinant of mRNA stability in vitro. Mol Cell Biol 1989; 9:659-70.
  77. Wells SE, Hillner PE, Vale RD, Sachs AB. Circularization of mRNA by eukaryotic translation initiation factors. Mol Cell 1998; 2:135-40.
  78. Borman AM, Michel YM, Malnou CE, Kean KM. Free poly(A) stimulates capped mRNA translation in vitro through the eIF4G-poly(A)-binding protein interaction. J Biol Chem 2002; 277:36818-24.
  79. Baer BW, Kornberg RD. Repeating structure of cyto- plasmic poly(A)-ribonucleoprotein. Proc Natl Acad Sci USA 1980; 77:1890-2.
  80. Sachs AB, Davis RW, Kornberg RD. A single domain of yeast poly(A)-binding protein is necessary and suf- ficient for RNA binding and cell viability. Mol Cell Biol 1987; 7:3268-76.
  81. Deo RC, Bonanno JB, Sonenberg N, Burley SK. Recognition of polyadenylate RNA by the poly(A)- binding protein. Cell 1999; 98:835-45.
  82. Couttet P, Fromont-Racine M, Steel D, Pictet R, Grange T. Messenger RNA deadenylylation precedes decapping in mammalian cells. Proc Natl Acad Sci USA 1997; 94:5628-33.
  83. Steitz J, Britten CM, Wölfel T, Tuting T. Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother 2006; 55:246-53.
  84. Martin G, Keller W. Tailing and 3'-end labeling of RNA with yeast poly(A) polymerase and various nucleotides. RNA 1998; 4:226-30.
  85. Korner CG, Wahle E. Poly(A) tail shortening by a mammalian poly(A)-specific 3'-exoribonuclease. J Biol Chem 1997; 272:10448-56.
  86. Rabinovich PM, Komarovskaya ME, Ye ZJ, Imai C, Campana D, Bahceci E, Weissman SM. Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther 2006; 17:1027-35.
  87. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells trans- fected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-34.
  88. Waggoner SA, Liebhaber SA. Identification of mRNAs associated with alphaCP2-containing RNP complexes. Mol Cell Biol 2003; 23:7055-67.
  89. Yu J, Russell JE. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. Mol Cell Biol 2001; 21:5879-88.
  90. Jiang Y, Xu XS, Russell JE. A nucleolin-binding 3' untranslated region element stabilizes beta-globin mRNA in vivo. Mol Cell Biol 2006; 26:2419-29.
  91. Holcik M, Liebhaber SA. Four highly stable eukary- otic mRNAs assemble 3' untranslated region RNA- protein complexes sharing cis and trans components. Proc Natl Acad Sci USA 1997; 94:2410-4.
  92. Al-Zoghaibi F, Ashour T, Al-Ahmadi W, Abulleef H, Demirkaya O, Khabar KS. Bioinformatics and experimental derivation of an efficient hybrid 3' untranslated region and use in expression active lin- ear DNA with minimum poly(A) region. Gene 2007; 391:130-9.
  93. Zinckgraf JW, Silbart LK. Modulating gene expres- sion using DNA vaccines with different 3'-UTRs influences antibody titer, seroconversion and cyto- kine profiles. Vaccine 2003; 21:1640-9.

Cited by

Sorted by citations

Authors
Kuhn, A. N., Diken, M., Kreiter, S., Vallazza, B., Türeci, Ö., & Sahin, U.
Affiliations
Johannes Gutenberg University Mainz (DE)
ORCID
Venue
RNA Biology
Publisher
Informa UK Limited
Published
2011-01
Volume
8
Issue
1
Pages
35-43
ISSN
  • 1547-6286 (ISSN-L)
  • 1555-8584
DOI
10.4161/rna.8.1.13767
OpenAlex
W2055918824
Cited by
39
References
7
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 2 · 2018: 4 · 2016: 3 · 2015: 3 · 2014: 5 · 2013: 7 · 2012: 2
FWCI
1.99
Type
journal article
Language
en
Open access
Locations
  • RNA Biology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Deutsche Forschungsgemeinschaft (SFB 432)
  • Bundesministerium für Bildung und Forschung
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
Keywords
RNA vaccines, dendritic cells, antigen-presenting cells, cancer immunotherapy, RNA stability, translation efficiency, 5' cap, poly(A) tail, cis-regulatory elements, trans-acting factors, antigen-specific immune response
MeSH terms
Dendritic Cells, Humans, Immunotherapy, Neoplasms, Poly A, RNA, RNA Caps, Deoxyribonucleases, Type II Site-Specific, Antigen Presentation, Cancer Vaccines, 3' Untranslated Regions, RNA Stability, Polyadenylation, Poly(A)-Binding Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review